July 11 — 14 Vienna, Austria

Meeting At A Glance
July 11 — 14

American Society of
Retina Specialists
33rd Annual Meeting
Vienna, Austria

EVENT LOCATIONS

Breakfast Included in your room rate at
ASRS host hotels

General Sessions Austria Center Vienna Hall A, level 2

Retina Case Conference Austria Center Vienna Hall A, level 2

Breaks Austria Center Vienna Hall F, level 0

Lunches Austria Center Vienna Hall F, level 0

Welcome Reception Palais Liechtenstein

Scientific Posters Austria Center Vienna Hall F, level 0

PAT Survey Posters Austria Center Vienna Hall F, level 0

Exhibits Austria Center Vienna Hall F, level 0

Paper on Demand (POD) Kiosks Austria Center Vienna Hall F, level 0

3D Video Kiosks Austria Center Vienna Hall F, level 0

Film Festival Kiosks Austria Center Vienna Hall F, level 0

Instructional Courses Friday, July 10:
InterContinental Wien Hotel Ballrooms 1-4
Johannesgasse 28, Wien

Monday, July 13 and Tuesday, July 14:
Austria Center Vienna Hall A, level 2 and
Hall E, level 0

Foundation Event Hotel Imperial reception and Musikverein

Gala Dinner Vienna City Hall

Speaker-Ready Room Room 2.31 level 2

Women in Retina (WinR) Lunch Austria Center Vienna Hall E, level 0

Young Physicians Section Lunch Austria Center Vienna Hall E, level 0

The American Society of Retina Specialists is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Retina Specialists designates this live activity for a maximum
of 28.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.

Disclosure Information
In accordance with the ACCME’s Standards for Commercial Support, ASRS required all
individuals controlling the content of this CME activity to disclose any relevant financial
relationships with commercial interests. ASRS implemented mechanisms to manage
any conflicts of interest. Please see the program booklet (our mobile meeting site) for
disclosure information for all planners and teachers of this CME activity.

F R I D A Y , J U L Y 1 0 (pre-meeting programming)

1:00-5:15 PM Instructional Courses (InterContinental Wien Hotel)

1:00-2:15 PM Challenge the Masters,
Ballroom Gabriela Lopezcarasa Hernandez, MD; Calvin E. Mein, MD;
Section 1-2 Virgilio Morales-Canton, MD; Hugo Quiroz-Mercado, MD

1:00-2:15 PM Surgical Management of Complicated Retinal Detachments,
Ballroom Alay S. Banker, MD
Section 3-4 Faculty: Jay Chhablani, MD; Hemanth Murthy, MBBS, MD;
Manish Nagpal, MD, FRCS (UK); S. Natarajan, MD

2:30-3:45 PM Newer Advances in Vitreo-Retinal Surgeries: Tools and
Ballroom Techniques, S. Natarajan, MD
Section 1-2 Faculty: Alay S. Banker, MD; Ehab N. El-Rayes, MD, PhD;
Manish Nagpal, MD, FRCS (UK); Stanislao Rizzo, MD

2:30-3:45 PM Uveitis Controversies on the Blue Danube, Steven Yeh, MD
Ballroom Faculty: Thomas A. Albini, MD; Howard F. Fine, MD, MHSc;
Section 3-4 Purnima S. Patel, MD; Francesco Pichi, MD;
Sunil Srivastava, MD; Robert C. Wang, MD

4:00-5:15 PM Vitreoretinal Surgical Techniques (How Do I Do It?):
Ballroom Video Panel, Ehab N. El-Rayes, MD, PhD
Section 1-2 Faculty: Carl Claes, MD; Pravin U. Dugel, MD;
Tarek S. Hassan, MD; Kazuaki Kadonosono, MD;
Carlos Mateo, MD; Yusuke Oshima, MD, PhD;
Kourous A. Rezaei, MD; Stanislao Rizzo, MD;
Malhar Soni, DO, MS, DNB, FRCS

4:00-5:15 PM Vitreoretinal Surgical Rounds. What Would Machemer Do?
Ballroom 40 Years of Evolution, Tamer H. Mahmoud, MD, PhD
Section 3-4 Faculty: Jose Garcia Arumi, MD, PhD; Susanne Binder, MD;
Sharon Fekrat, MD, FACS; Paul Hahn, MD, PhD;
Akito Hirakata, MD; Glenn J. Jaffe, MD;
Prithvi Mruthyunjaya, MD; Marco Mura, MD;
Sengul Ozdek, MD; Stanislao Rizzo, MD; Cynthia
Ann Toth, MD; Michael T. Trese, MD; Lejla Vajzovic, MD

ASRS ANNUAL MEETING | 1

S AT U R DAY, J U LY 1 1

8:00-8:05 AM Welcome, Mark S. Humayun, MD, PhD

8:05-8:35 AM AMD Neovascular 1
8:05 Long-Term (60-month) Results of the Implantable
8:13 Miniature Telescope, David Boyer, MD
Increased Risk of Surgical Complications,
8:21 Postoperative Glaucoma, and Endophthalmitis With
Cataract Surgery Following Intravitreal Injections,
8:29 Paul Hahn, MD, PhD
Evaluating the Effects of VEGF-Trap Eye on Patients
With Polypoidal Choroidal Vasculopathy: 3 Month
Interim Analysis of VAULT Study, Joo Eun Lee, MD
Discussion

8:35-8:50 AM AMD Neovascular 1-Rapid Fire Papers

8:35 Ziv-aflibercept in Macular Disease, Ahmad Mansour, MD

8:40 Intravitreal Ziv-Aflibercept for Treatment of Wet Age-
Related Macular Degeneration, Eduardo Rodrigues, MD

8:45 Discussion

8:50-9:20 AM AMD Neovascular 1-Expert Panel

Moderator: Timothy G. Murray, MD, MBA

8:50 Safety and Efficacy of RTH258 Delivered Via
Intravitreal Injection or Microvolume Injection/Infusion
for Neovascular Age-Related Macular Degeneration,
Rishi Singh, MD

8:53 What Predicts the Development of Macular Atrophy
in Wet AMD Patients Treated With Anti-VEGF?,
Pravin Dugel, MD

8:56 Final Results From a Phase 2 Study of Squalamine
Lactate Ophthalmic Solution 0.2% (OHR-102) in
Neovascular Age-Related Macular Degeneration (AMD),
Jeffrey Heier, MD

8:59 Overview of Conbercept Trials With Results of the
LAMP (Treatment of Very-Low-Vision Age-Related
Macular Degeneration Patients With Conbercept) Study,
Peter Kaiser, MD

9:02 Acute Sterile Endophthalmitis Following Intravitreal
Bevacizumab: Case Series in a Large Institution,
Virgilio Morales-Canton, MD

9:05 Discussion

9:20-10:05 AM Break

10:05-10:45 AM International Panel, Kourous A. Rezaei, MD

10:45-11:05 AM AMD Non-neovascular 1-Rapid Fire Papers

10:45 Panmacular Subthreshold Diode Micropulse laser (SDM)
Prophylaxis of Age-Related Macular and Inherited
Photoreceptor Degenerations, Jeffrey Luttrull, MD

10:50 Nucleoside Reverse Transcriptase Inhibitors Possess
Intrinsic Anti-Inflammatory Activity and Target Dry Age-
Related Macular Gegeneration, Jayakrishna Ambati, MD

10:55 Generating Human Retinal Cells From Skin Biopsies of
Patients With Advanced AMD, Lucian Del Priore, MD, PhD

11:00 Discussion

2 | 2015

11:05-11:35 AM AMD Non-neovascular-Expert Panel
Moderator: John T. Thompson, MD
11:05 Potential Public Health Impact of the Home Monitoring
Device Evaluated in the Age-Related Eye Disease
11:08 Study 2-Home Monitoring of the Eye Study,
Carl Regillo, MD, FACS
11:11 Understanding Geographic Atrophy Disease
11:14 Progression Through Visual Function Endpoints:
11:17 The Lampalizumab Phase 3 Clinical Trial Program,
Adnan Tufail, MBBS, MD, FRCOphth
Comparative Quantification of Geographic Atrophy
Across Manual and Automated Grading Using Color, Red-
Free, Autofluorescent, and OCT Images, Neil Bressler, MD
Intravitreal Erythropoietin in Eyes With Geographic
Atropy Secondary to Age-Related Macular Degeneration,
Stephen Sinclair, MD
Evaluation of Visual Acuity Measurements With
Standard Luminance Compared With Low Luminance
in Eyes With Geographic Atrophy From Age-Related
Macular Degeneration, Diana Do, MD

11:35 AM-12:50 PM Lunch

12:50-1:15 PM Socioeconomics

12:50 Austrian Real Life Data of Intravitreal Injections Show No
Benefit From Current Treatment, Gerhard Kieselbach, MD

12:58 The Commoditization of the Retinal Practice,
Mark Nelson, MD, MBA

1:06 Utilization of the Dexamethasone Implant for Diabetic
Macular Edema in US Clinical Practice: 2011-2014,
Michael Singer, MD

1:11 Discussion

1:15-1:45 PM State of the ASRS

1:15 Retina PractiCare-Leveraging the Power of Claims
Data, John Thompson, MD

1:23 Discussion

1:25 President’s Address, Tarek Hassan, MD

1:40 Discussion

1:45-2:45 PM Retinal Vascular Disease

1:45 Aflibercept for Radiation Retinopathy,
Liliya Shevchenko, DO

1:53 Proteomic Analysis of Vitreous Humor in Retinal
Vein Occlusion, Michael Koss, MD

2:01 What Step Changes in Diabetic Retinopathy (DR)
Look Like: Photographic Cases of Improvement With
Ranibizumab (RBZ), Baruch Kuppermann, MD, PhD

2:09 Squalamine Lactate Ophthalmic Solution for the
Treatment of Macular Edema Secondary to Branch and
Central Retinal Vein Occlusion. Final Data Analysis.,
John Wroblewski, MD

2:17 Discussion

2:24 Intravitreal Aflibercept Injection for Macular Edema
Following Branch Retinal Vein Occlusion: Outcomes
From the VIBRANT Study, Jennifer Lim, MD

2:29 The Impact of Cataract Surgery on Patients
With Diabetic Macular Edema (DME) Receiving
Ranibizumab, Andrew Moshfeghi, MD, MBA

ASRS ANNUAL MEETING | 3

2:34 Does Prior Treatment With Laser and/or Steroid
Impact Outcomes With Ranibizumab (RBZ) Therapy
for Diabetic Macular Edema (DME), J. Jumper, MD

2:39 Discussion

2:45-3:15 PM Break

3:15-4:15 PM Medical Case Conference

Moderators: Daniel F. Martin, MD and Neil M. Bressler, MD

Presenters:
Netan Choudhry, MD, FRCS(C)
Dilsher Dhoot, MD
Jorge Fortun, MD
Anshul Goyal, MD
Tara McCannel, MD, PhD
Rodrigo Meirelles, MD
Janusz Michalewski, MD, PhD
Quan Dong Nguyen, MD, MSc
Paula Pecen, MD
Armando Sandoval, MD
Daraius Shroff, MS, FMRF, FRCS

4:15-5:15 PM Surgical Case Conference

Moderators: Carl C. Awh, MD and Kourous A. Rezaei, MD

Presenters:
Hany Hamza, MD
Ashish Lall, MS, FRCS, DNB, MNAMS, FELLOW LVPEI,
FNB RETINA
Tatsushi Kaga, MD, PhD
Kamal Kishore, MD, MBBS
Colin McCannel, MD
Jeffrey Olson, MD
Sengul Ozdek, MD
Aleksandra Rachitskaya, MD
Michael Seider, MD
Homayoun Tabandeh, MD
John Thompson, MD
Christina Weng, MD, MBA
Leandro Zacharias, MD

7:00-10:00 PM Opening Reception

4 | 2015

S U N DAY, J U LY 1 2 , 2 0 1 5

8:00-8:35 AM Diabetic Retinopathy 1

8:00 Anti-VEGF Treatment of Diabetic Macular Edema
in Clinical Practice: A Retrospective Study of
Effectiveness and Patterns of Use, Kevin Blinder, MD

8:08 SSADA Assisted Angio-OCT Confirms Attenuation
of Deep Capillary Macular Vascular Flow Index in
Nonproliferative Diabetic Retinopathy,
K. Chalam, MD, PhD, MBA, FRCS(C)

8:16 Randomized Trial of Prompt Panretinal
Photocoagulation vs. Ranibizumab and Deferred
Panretinal Photocoagulation for Proliferative Diabetic
Retinopathy, Jennifer Sun, MD

8:24 Benefit-Risk Analysis of Phase 3 Clinical Trial Data
Comparing Ranibizumab With Laser Treatment in
Diabetic Macular Edema, Alan Cruess, MD, FRCS(C)

8:29 Discussion

8:35-9:05 AM Diabetic Retinopathy-Expert Panel

Moderator: Tarek S. Hassan, MD

8:35 Intravitreal Aflibercept for Diabetic Macular Edema:
148-Week Results From the VISTA Trial, David Brown, MD

8:38 Comparative Effectiveness Randomized Clinical Trial of
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic
Macular Edema, Carl Baker, MD

8:41 Comparative Effectiveness of Intravitreous Aflibercept,
Bevacizumab, or Ranibizumab for DME in a
Randomized Trial: Treatment and Safety Outcomes,
Andrew Antoszyk, MD

8:44 Ranibizumab (0.3 mg) for Persistent Diabetic Macular
Edema (DME) After Recent, Frequent and Chronic
Bevacizumab (ROTATE Trial): Six Month Results,
Dennis Marcus, MD

8:47 Intravitreal Aflibercept Injection: Outcomes in DME
Eyes With Very Limited Initial Anatomic Response
in VISTA/VIVID Studies Through Weeks 52 and 100,
Dante Pieramici, MD

8:50 Discussion

9:05-9:50 AM Break

9:50-11:25 AM Awards Ceremony
9:50 Pyron Award Introduction
9:55 Pryron Award, Gary W. Abrams, MD (lecture title TBD)
10:25 Founders Award Introduction
10:30 Founders Award, Richard F. Spaide, MD, Optical
Coherence Tomography Angiography: The Reality Today
11:00 and the Potential for the Future
11:05 Young Physicians Section (YPS), Crystal Apple Award
11:10 ASRS Presidents’ Retina Young Investigators Award

Yearly Progression Rates of Atrophic Lesions Measured
by Fundus Autofluorescence in the Retrospective
ProgStar Study, Hendrik P. Scholl, MD, MA

11:25 AM-12:40 PM Lunch

ASRS ANNUAL MEETING | 5

12:40-1:50 PM Retinal Detachment

12:40 Removing Swollen Hydrogel Explants (MIRAgel); Risk
for Retinal Redetachment and Scleral Perforation in
467 Consecutive Cases, Niels Crama, MD

12:48 Adaptive Optics Imaging and Quantitative Analysis of
Photoreceptors Following Repair of Rhegmatogenous
Retinal Detachments, Meenakashi Gupta, MD

12:56 Outcomes and Complications of Densiron Intraocular
Tamponade for Retinal Detachment Repairs: A
Retrospective Chart Review, Amin Kherani, MD

1:04 Characterization of the Retinoschisis Outer Retinal
Holes by Optical Coherence Tomography,
Aleksandra Rachitskaya, MD

1:12 Discussion

1:18 Suprachoroidal Buckling Complications During
Learning Curve, Flavio Rezende, MD, PhD

1:26 Subchoroidal Hemorrage After Blunt Trauma
in Previous PK Ssing “Pole to Pole” Strategy:
Overcoming a Taboo, Cesare Forlini, MD

1:34 Chandelier-Assisted Scleral Buckle for Repair of
Primary Rhegmatogenous Retinal Detachment,
Michael Seider, MD

1:39 Scleral Buckling With Wide Angled Endoillumination
as a Surgical Educational Tool, Raja Narayanan, MD

1:44 Discussion

1:50-2:05 PM Surgical Techniques and Maneuvers

1:50 Multiple Posterior Vitreous Layers in Retinal
Detachment and Diabetic Proliferative Retinopathy,
James Folk, MD

1:58 Discussion

2:05-2:50 PM Instrumentation and Devices

2:05 Can Reading Speed or Video Scanning Laser
Ophthalmoscopy Objectively Assess the Subjective
Visual Improvement After Surgery for Vitreous
Opacities?, Linda Lam, MD

2:13 Feasibility and Utility of Microscope-Integrated
Intraoperative OCT for Vitreoretinal Surgery: The
DISCOVER Study 1-Year Results, Justis Ehlers, MD

2:21 Fluid Dynamics of Vitrectomy Probes: The Quest
for a Perfect Cutter, Tommaso Rossi, MD, EBOD

2:29 Discussion

2:34 Fluidics Analysis and Histopathological Findings With
a New Prototype of Ultrasound Harmonics Vitrector
(UHV): First Report, Paulo Stanga, MD

2:42 Pilot Study of Feasibility of Use of Experimental High
Viscosity Silicone Oils, Alex Rubowitz, MD

2:47 Discussion

6 | 2015

2:50-3:20 PM Surgical Techniques and Maneuvers-Expert Panel

Moderator: Carl C. Awh, MD

2:50 Comparison of 25 Versus 27-Gauge for Vitreoretinal
Surgery, Jared Nielsen, MD

2:53 Comparison of Iris-Sutured, Scleral-Sutured and Glued
Intraocular Lens Implantation Techniques in Aphakic
Patients, Gennady Landa, MD

2:56 Vitreomacular Traction Syndrome: Postoperative
Functional and Anatomic Outcomes,
Mauricio Maia, MD, PhD

2:59 Surgically Integrated 4-Dimensional, Swept-Source
Optical Coherence Tomography (SSOCT) With Heads
Up Display to Guide Vitreoretinal Surgery,
Cynthia Toth, MD

3:02 Does Vitreous Status (Attached/Detached) Affect
Visual Outcome in Patients Undergoing Vitrectomy for
Floaters, Rubina Rahman, MBBS, FRCOpth, FRCS

3:05 Discussion

3:20-4:00 PM Break

4:00-4:50 PM Retinal Imaging in the Computer Age: The Future Is
the Presence, Ursula Schmidt-Erfurth, MD
Faculty: Hrvoje Bogunovic, PhD; Bianca S. Gerendas, MD;
Alessio Monturo, MSc; Sebastian M. Waldstein, MD

4:50-5:15 PM Revolutionary Retina, Suber S. Huang, MD, MBA
Faculty: Jeffrey S. Heier, MD; Darius M. Moshfeghi, MD;
Stanislao Rizzo, MD

5:15-6:15 PM Scientific Posters & Exhibit Hall Reception

ASRS ANNUAL MEETING | 7

M O N DAY, J U LY 1 3

8:00-9:20 AM AMD Neovascular 2

8:00 Age-Related Macular Degeneration and Aspirin Use,
Kent Small, MD

8:08 Influence of the Vitreomacular Interface on Treatment
Outcomes in the Comparison of AMD Treatments
Trials (CATT), Thomas Ciulla, MD

8:16 Prospective, Multicenter Investigation of Aflibercept
Treat and Extend Therapy for Neovascular Age-Related
Macular Degeneration, Francis DeCroos, MD

8:24 Discussion

8:29 How Do Large Pigment Epithelial Detachments
Respond to Ranibizumab Treatment in Wet AMD
Patients?, David Eichenbaum, MD

8:37 Factors Influencing Dose Accuracy and Variation of
Anti-VEGF Drug Injections, Raymond Iezzi, MD, MS

8:45 En Face Optical Coherence Tomography Imaging of
Polypoidal Choroidal Vasculopathy (PCV) Diagnosed
With Indocyanine Green (ICG) Angiography,
Gregg Kokame, MD, MMM

8:53 Discussion

8:58 Long-Term Vision and Anatomic Outcomes for
Neovascular Age-Related Macular Degeneration
(NVAMD) Patients in the Anti-VEGF Era,
George Parlitsis, MD

9:06 Fluorescein Angiography Features Predictive of
Polypoidal Choroidal Vasculopathy: A Post-hoc Analysis
From the Randomized Controlled EVEREST Study,
Colin Tan, MBBS, MMed (Ophth), FRCSEd (Ophth)

9:14 Discussion

9:20-9:40 AM AMD Neovascular 2-Rapid Fire Papers
9:20 Gene Therapy: The Next Frontier in the Management
of Neovascular Age-Related Macular Degeneration
9:25 (nAMD) and Other Acquired and Inherited Disorders,
Szilard Kiss, MD
9:30 Intravitreal Bevacizumab for Choroidal
9:35 Neovascularization Secondary to Age-Related Macular
Degeneration: 5-Year Results of the PACORES Group,
Lihteh Wu, MD
The Top 10 Practical Pearls From the HARBOR Trial
of Ranibizumab in Neovascular (wet) Age-Related
Macular Degeneration (wAMD), Victor Gonzalez, MD
Discussion

9:40-10:30 AM Break

10:30-10:50 AM Pediatric Retina-ROP

10:30 Telemedicine Diagnosis of Plus Disease in
Retinopathy of Prematurity: Accuracy of Expert
Versus Computer-Assisted Quantitative Vascular
Analysis, Ashkan Abbey, MD

10:38 Neurodevelopmental Outcomes in Infants With
Retinopathy of Prematurity and Bevacizumab
Treatment, Wei-Chi Wu, MD, PhD

10:46 Discussion

8 | 2015

10:50-11:20 AM Pediatric Retina-ROP-Expert Panel

Moderator: Philip J. Ferrone, MD

10:50 Fundus Pigmentation as a Risk Factor for Development
of Retinopathy of Prematurity, Audina Berrocal, MD

10:53 Fluorescein Angiography for the Diagnosis and
Management of Retinopathy of Prematurity,
Michael Klufas, MD

10:56 Retinal Detachments After Intravitreal Anti-VEGF
Injections for Retinopathy of Prematurity,
Antonio Capone, MD

10:59 Local and Systemic Adverse Events After
Intravitreal Bevacizumab in the Treatment of
Retinopathy of Prematurity in a Nine Year Period,
Maria Martinez-Castellanos, MD

11:02 Newborn Infant Global Universal Eye Screen Testing
(GUEST) Study: Validation of Technique Approach,
Darius Moshfeghi, MD

11:05 Discussion

11:20 AM-12:00 PM Ocular Oncology

11:20 Application of Results of Cytopathological Analysis
and Gene Expression Profile in Clinically Diagnosed
Posterior Uveal Melanomas Evaluated by FNAB,
Zelia Correa, MD, PhD

11:28 Iodine-125 Brachytherapy for Extra-Large Choroidal
Melanomas: Benefit of Vitrectomy and Silicone Oil on
Visual Acuity, Tara McCannel, MD, PhD

11:36 Peripheral Retinal Perfusion Correlates With Radiation
Retinopathy Status Following I-125 Brachytherapy for
Uveal Melanoma, Prithvi Mruthyunjaya, MD

11:44 Intravitreal Pharmacotherapy for Radiation
Maculopathy (IRM Study): 5-year Follow-Up Detailing
Treatment Extension and Enhanced Outcomes,
Timothy Murray, MD, MBA

11:52 Discussion

12:00-1:15 PM Lunch

1:15-2:15 PM Inflammatory and Infectious Diseases
1:15 Injectable Long-Acting Intravitreal Floucinolone
Acetonide Implant to Treat Non-infectious
1:23 Intermediate, Posterior or Panuveitis, Glenn Jaffe, MD
Treatment of Cytomegalovirus (CMV) Retinitis With
1:31 Third Party Donor-Derived CMV-Specific Cytotoxic
1:39 T-lymphocytes, Mrinali Gupta, MD
The Utility of 2z Ultra-Wide Fluorescein Angiography in
1:47 the Management of Uveitis Patients, Sunil Srivastava, MD
1:53 Analyses of SAVE-2: A Phase 2 Study to Assess the
Safety and Efficacy of Two Doses of Intravitreal
Sirolimus in Patients With Noninfectious Uveitis,
Quan Nguyen, MD, MSc
Discussion
Intravitreal Sirolimus Monotherapy Reduces the
Corticosteroid Treatment Burden in Subjects With NIU
of the Posterior Segment: SAKURA Study 1 Results,
Pauline Merrill, MD

ASRS ANNUAL MEETING | 9

1:58 The Importance of Using Povidone-Iodine and Elimination
of Topical Antibiotics for Intravitreous Injections:
Update From the DRCR.net, Abdhish Bhavsar, MD

2:03 Varicella Zoster Virus (VZV) Antigen Presence and
Distribution in Giant Cell Arteritis (GCA) Positive
Temporal Artery (TA) Biopsies, Naresh Mandava, MD

2:08 Discussion

2:15-2:35 PM Hereditary Retinal Disease & Genetics

2:15 Effectiveness of Dexamethasone Intravitreal Implant
in Refractory Macular Edema Due to Retinitis
Pigmentosa, Cem Kucukerdonmez, MD

2:23 Whole Exome Sequencing Identifies Rare Genetic
Variants in Age-Related Macular Degeneration Patients,
Eran Pras, MD

2:31 Discussion

2:35-3:10 PM Pharmacology
2:35 Pericentral Hydroxychloroquine Retinopathy in
2:43 Korean Patients, Young Hee Yoon, MD
Anti-Angiogenics in Iatrogenic Choroidal
2:48 Neovascularization in Central Serous
2:53 Chorioretinopathy, Jay Chhablani, MD
MEK Inhibitor-Associated Subretinal Fluid,
2:58 Marissa Weber, MD
3:03 Bilateral Macular Neurosensory Retinal Detachment
Associated With MEK Inhibitor Use for Metastatic
Cancer: A Case Series and Review of the Literature,
Seenu Hariprasad, MD
PRN Dexamethasone Implant for Macular Edema,
Michel Farah, MD, PhD
Discussion

3:10-4:00 PM Break

4:00 4:50 PM RETINAWS: When the Going Gets Tough, the Tough
Get Going, Challenging Cases in Vitreoretinal Surgery,
Kourous Rezaei, MD

Faculty: Jose Garcia Arumi, MD, PhD; Susanne Binder, MD;
Stratos V. Gotzaridis, MBBS, MD; Nikoloz Labauri, MD,
FVRS; Kirk H. Packo, MD, FACS; Grazia Pertile, MD;
Homayoun Tabandeh, MD

10 | 2 0 1 5

T U E S DAY, J U LY 1 4

8:00-8:25 AM Business Meeting-ASRS Members Only

8:25-8:30 AM PAT Survey Presentation

8:30-10:15 AM Diabetic Retinopathy 2

8:30 Rescue Treatment With Intravitreal Aflibercept
Injection in Patients With Diabetic Macular Edema
(DME) Randomized to Laser in VISTA and VIVID,
Charles Wykoff, MD, PhD

8:38 Systemic Safety of Intensive Use of Intravitreal
Anti-VEGF Agents for Diabetic Macular Edema,
Robert Avery, MD

8:46 Switching Treatment for DME From Bevacizumab
to Ranibizumab: Who is Likely to Benefit From the
Switch?, Gabriel Katz, MD

8:54 Discussion

8:59 Vitrectomy in the Management of Diabetic
Macular Edema in Treatment-Naïve Patients,
Jerzy Nawrocki, MD, PhD

9:07 The Cardiovascular and Cerebrovascular Safety
Profile of Intravitreal Ranibizumab (RBZ) in DME:
A Pooled Analysis of 6 Phase II/III Clinical Trials,
Marco Zarbin, MD, PhD

9:15 Discussion

9:20 Prospective, Randomized, Subject Masked Study
of Intravitreal Bevacizumab Versus Dexamethasone
Implant in the Treatment of Diabetic Macular Edema,
Raj Maturi, MD

9:25 Targeted Retinal Photocoagulation (TRP) vs
Vitrectomy With ILM Peeling to Treat Recalcitrant
Diabetic Macular Edema-A Comparative Study,
Subhendu Boral, MBBS, MD (AIIMS), DNB
(OPHTHALMOLOGY)

9:30 Visual and Anatomic Outcomes After Addition of
Triamcinolone Acetonide to Anti-VEGF Compared to
Anti-VEGF Monotherapy for Diabetic Macular Edema,
Petros Carvounis, MD, FRCSC

9:35 Discussion

9:40 PASCAL Panretinal Photocoagulation (PRP) Versus
ETDRS-PRP With Intravitreal Ranibizumab (IVR)
Versus IVR Only for Proliferative Diabetic Retinopathy,
Rodrigo Jorge, MD

9:45 Vitreous Levels of Endolthelial Nitric Oxide Synthase
S1177 are Inversely Related to Severity of Diabetic
Macular Edema, Matthew Katz, MD

9:50 Discussion

9:55 Intravitreal Bevacizumab Alone or Combined With
1mg Triamcinolone in Diabetic Macular Edema. A
Randomized Clinical Trial, Mohammad Riazi, MD

10:00 The Cost-Effectiveness of Anti-VEGF Treatments for
Diabetic Macular Edema, Nancy Holekamp, MD

10:05 Prevalence of Diabetic Macular Edema Based on
Monocular Fundus Photography vs Optical Coherence
Tomography, Susan Bressler, MD

10:10 Discussion

10:15-11:00 AM Break

A S R S A N N U A L M E E T I N G | 11

11:00 AM-12:00 PM Macular Pucker-Epiretinal Membrane

11:00 Efficacy and Safety of Pneumatic Vitreolysis,
Ocriplasmin and Vitrectomy for Symptomatic
Vitreomacular Adhesions: A Case Series and
Meta-Analysis, Jorge Arroyo, MD, MPH

11:08 Results of Using Membrane Blue Dual in Epiretinal
Membrane and Macular Hole Surgery Without Face
Down Position, Boris Bajaire, MD

11:16 25-Gauge Pars Plana Vitrectomy (PPV) for Myopic
Foveoschisis (MF), Francesco Boscia, MD

11:24 Discussion

11:30 Epiretinal Membrane Peeling in Patients With Good
Starting Pre-op Vision, Nicholas Chinskey, MD

11:38 Optical Coherence Tomography Assisted Predictors
of Visual Outcome in Epiretinal Membrane Removal,
Srinivas Joshi, MD

11:46 Swept-Source OCT correlations Between Retina and
Choroid Before and After Vitrectomy for Epiretinal
Membranes, Janusz Michalewski, MD, PhD

11:54 Discussion

12:00-1:15 PM Lunch

1:15-2:30 PM Macular Holes

1:15 Initial Outcomes Following Intravitreal Ocriplasmin for
Treatment of Symptomatic Vitreomacular Adhesion:
A Canada-Wide Study, Netan Choudhry, MD, FRCS(C)

1:23 Intravitreal Perfluoropropane Gas (C3F8) Versus
Ocriplasmin for the Treatment of Vitreomacular
Traction (VMT), Nathan Steinle, MD

1:31 The Combined Tractional-Hydration Theory of
Idiopathic Macular Holes, Ronald Gentile, MD

1:39 Discussion

1:44 Pneumatic Vitreolysis for Treatment of Focal
Vitreomacular Traction and Early Small Macular Holes,
Calvin Mein, MD

1:52 Subretinal BSS injection: A Technique for the
Treatment of Chronic Persistent Macular Holes,
Rajeev Muni, MD, MSC, FRCSC

2:00 Discussion

2:05 The Aborted Macular Hole: An Optical Coherence
Tomography Study, Steven Agemy, MD

2:10 Correlation of Foveal Microstructure and Lucencies
Assessed Using High-Density SDOCT Radial Scans
With Visual Recovery Following Macular Hole Surgery,
Dilraj Grewal, MD

2:15 The Outer Choroidoscleral Boundary in Full-Thickness
Macular Holes Before and After Surgery-A Swept
Source OCT Study, Zofia Michalewska, MD, PhD

2:20 Infracyanine Green Versus Brillant Blue G in Macular
Hole Surgery, Christiane Falkner-Radler, MD

2:25 Discussion

2:30-3:15 PM Imaging-Digital-Angiography
2:30 Comparison of Choroidal Thickness in Unilateral
Central Serous Chorioretinopathy (CSCR) in Acute
and Resolved Phases Versus Normal Control Eyes,
Alay Banker, MD

12 | 2 0 1 5

2:38 Correlation of Vitreomacular Traction With Foveal
Thickness, Subfoveal Choroidal Thickness and
Vitreomacular Angle, Igor Kozak, MD, PhD

2:43 SD-OCT Findings of Presence of Spherical
Hyperreflective Bodies in Sub Silicone Oil Space and
Visual Outcomes in Eyes Undergoing Silicone Oil
Removal, Manish Nagpal, MD, FRCS (UK)

2:48 Discussion

2:54 Efficacy of Intravitreal Bevacizumab in Eyes With
Myopic Choroidal Neovascularization Without
Intraretinal or Subretinal Fluid on Spectral-domain
OCT, Randee Miller, MD

2:59 Diabetic Retinopathy (DR) Severity and Predominantly
Peripheral DR Lesions are Associated With
Nonperfusion on Ultrawide Field Angiography,
Paolo Antonio Silva, MD

3:04 High Resolution (23x35 Microns), Real-Time Anterior
Segment B-scan Ultrasonopgraphy for the Posterior
Segment Surgeon, Yale Fisher, MD

3:09 Discussion

3:15-3:45 PM Imaging-Digital-Angiography: Expert Panel

Moderator: John S. Pollack, MD

3:15 OCT Angiographic Perfusion Mapping of Macular
Vascularity in Diabetic and Normal Subjects,
Richard Rosen, MD, DSc(Hon)

3:18 Six-Year Utilization Patterns of Ophthalmic Imaging
Tests In Patients With Retinal Diseases, Jorge Fortun, MD

3:21 Prognostic Value of Optical Coherence Tomography Based
Classification of Myopic Choroidal Neovascularization,
Roberto Gallego-Pinazo, MD, PhD, DiSSO

3:24 Optical Coherence Tomography Angiography in
Retinal Disease, Amir Kashani, MD PhD

3:27 Ultra-Widefield Imaging of the Peripheral Retinal
Vasculature in Normal Subjects, Srinivas Sadda, MD

3:30 Discussion

3:45-4:15 PM Break

4:15-5:05 PM ASRS Research and Development Committee
Symposium: Clinical Trials “Unplugged” Real,
Practical Questions and Answers, Pravin Dugel, MD
Faculty: Carl C. Awh, MD; David S. Boyer, MD;
David M. Brown, MD; Antonio Capone, MD;
Tarek S. Hassan, MD; Jeffrey S. Heier, MD;
J. Michael Jumper, MD; Peter K. Kaiser, MD;
Baruch D. Kuppermann, MD, PhD;
Timothy G. Murray, MD, MBA; John S. Pollack, MD;
Carl D. Regillo, MD, FACS; Philip J. Rosenfeld, MD, PhD;
John T. Thompson, MD

4:15-5:05 PM Incorporating Argus II Retinal Prosthesis into
Practice: Surgical Candidate Selection, Surgical
Procedure, and Post-implant Course, Ninel Gregori, MD
Faculty: J. Fernando Arevalo, MD, FACS;
Mark S. Humayun, MD, PhD; Stanislao Rizzo, MD

7:00-11:30 PM Closing Dinner

A S R S A N N U A L M E E T I N G | 13